A new study offers hope for improving CAR-T cell therapy in treating B-cell Acute Lymphoblastic Leukemia (B-ALL), a cancer with high relapse rates. Researchers have developed an innovative approach involving a TIM-3 decoy that prevents immune evasion by leukemia cells...
Avance Biosciences is excited to join WRIB 2025 in New Orleans, showcasing our expertise in bioanalytical testing for biologics and biosimilars. Visit us at Booth #78 to explore our advanced solutions, including LBA, Flow Cytometry, qPCR, and LC-MS/MS. [...]
Beam Therapeutics announces groundbreaking results from its Phase 1/2 trial of BEAM-302, demonstrating the first-ever clinical genetic correction for Alpha-1 Antitrypsin Deficiency (AATD), offering hope for a potential one-time cure for this genetic disorder...
TIGR (Tandem Interspaced Guide RNA) systems use RNA guides to target specific DNA sites, offering a compact and modular alternative to CRISPR. Scientists at MIT and the Broad Institute discovered over 20,000 TIGR-associated proteins, some capable of precise DNA cutting, potentially expanding genome...
Avance Biosciences is excited to announce its participation in the upcoming SITC Conference, taking place from November 6-10, 2024, in Houston TX. This premier event is focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. [...]
Avance Biosciences™ offers top-tier GLP & GMP compliant services in assay development, validation, & sample testing for biopharma. Visit our booth to explore how we support drug discovery, development, & manufacturing with precision & expertise. [...]
Avance Biosciences is excited to announce its participation in the upcoming Immunogenicity & Bioassay Summit, taking place from October 15-18, 2024, in Washington, DC. As the premier immunogenicity and bioassay event in the U.S., this summit provides an excellent platform for us to connect with industry [...]
Avance Biosciences is excited to announce its participation in the upcoming 2nd CRISPR-Based Therapy Analytical Development Summit, taking place from September 17-19, 2024, in Boston, MA. This premier event is a key gathering for professionals and innovators in the gene editing and CRISPR fields.[...]
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...
Tecelra is the first FDA-approved T cell receptor (TCR) gene therapy. The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells in Tecelra are modified to express a TCR that targets MAGE-A4, an antigen expressed by cancer cells in synovial sarcoma...
